Our Research

Manuscripts

1: Health resource utilization and costs during the first 90 days following robot-assisted hysterectomy. Int Urogynecol J. 2018 Jun;29(6):865-872.
https://www.ncbi.nlm.nih.gov/pubmed/28785778

2: Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn. 2017 Nov;36(8):2123-2131.
https://www.ncbi.nlm.nih.gov/pubmed/28467609

3: Comparative analysis of overall cost and rate of healthcare utilization among apical prolapse procedures. Int Urogynecol J. 2017 Oct;28(10):1481-1488.
https://www.ncbi.nlm.nih.gov/pubmed/28364131

4: Mesh complications and failure rates after transvaginal mesh repair compared with abdominal or laparoscopic sacrocolpopexy and to native tissue repair in treating apical prolapse. Int Urogynecol J. 2017 Feb;28(2):215-222.
https://www.ncbi.nlm.nih.gov/pubmed/27562466

5: First-Line Fixed-Combination Psoriasis Treatment Is Associated With Lower Healthcare Costs. Skinmed. 2016 Aug 1;14(4):266-272.
https://www.ncbi.nlm.nih.gov/pubmed/27784515

6: Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs. J Med Econ. 2013 Dec;16(12):1405-13.
https://www.ncbi.nlm.nih.gov/pubmed/24063352

7: Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey. J Comp Eff Res. 2012 Sep;1(5):453-63.
https://www.ncbi.nlm.nih.gov/pubmed/24236422

8: Weighing the evidence for pediatric antipsychotic use. Psychiatr Serv. 2010 Mar;61(3):325.
https://www.ncbi.nlm.nih.gov/pubmed/20194416

9: Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010 Feb;61(2):123-9.
https://www.ncbi.nlm.nih.gov/pubmed/20123816

10: Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann Pharmacother. 2009 May;43(5):840-8.
https://www.ncbi.nlm.nih.gov/pubmed/19417111

11: Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients. Curr Med Res Opin. 2019 Oct;35(10):1769-1776.
https://www.ncbi.nlm.nih.gov/pubmed/31120309

12: Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. J Am Geriatr Soc. 2019 Aug;67(8):1662-1671.
https://www.ncbi.nlm.nih.gov/pubmed/31112292

13: Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. J Thromb Thrombolysis. 2019 Aug;48(2):240-249.
https://www.ncbi.nlm.nih.gov/pubmed/30924051

14: Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PLoS One. 2019 Mar 25;14(3):e0213614.
https://www.ncbi.nlm.nih.gov/pubmed/30908512

15: Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States. Adv Ther. 2019 Jan;36(1):162-174.
https://www.ncbi.nlm.nih.gov/pubmed/30499067

16: Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619870249.
https://www.ncbi.nlm.nih.gov/pubmed/31418293

17: Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2017 Feb 23;12:735-744.
https://www.ncbi.nlm.nih.gov/pubmed/28260880

18: Association between adherence to medications for COPD and medications for other chronic conditions in COPD patients. Int J Chron Obstruct Pulmon Dis. 2016 Dec 22;12:115-122.
https://www.ncbi.nlm.nih.gov/pubmed/28053521

19: Associations Between COPD Severity and Work Productivity, Health-Related Quality of Life, and Health Care Resource Use: A Cross-Sectional Analysis of National Survey Data. J Occup Environ Med. 2016 Jun;58(6):e191-7.
https://www.ncbi.nlm.nih.gov/pubmed/27206123

20: COPD exacerbation frequency and its association with health care resource utilization and costs. Int J Chron Obstruct Pulmon Dis. 2015 Dec 3;10:2609-18.
https://www.ncbi.nlm.nih.gov/pubmed/26664109

21: Development and Validation of a Predictive Model to Identify Individuals Likely to Have Undiagnosed Chronic Obstructive Pulmonary Disease Using an Administrative Claims Database. J Manag Care Spec Pharm. 2015 Dec;21(12):1149-59.
https://www.ncbi.nlm.nih.gov/pubmed/26679964

22: Factors associated with inpatient readmission among managed care enrollees with COPD. Hosp Pract (1995). 2015;43(4):199-207.
https://www.ncbi.nlm.nih.gov/pubmed/26357878

23: Clinical and economic burden of COPD in a medicaid population. COPD. 2014 Apr;11(2):212-20.
https://www.ncbi.nlm.nih.gov/pubmed/24111752

24: Metabolic monitoring of patients prescribed second-generation antipsychotics. J Psychiatr Pract. 2013 Sep;19(5):360-74.
https://www.ncbi.nlm.nih.gov/pubmed/24042242

25: Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012 Dec;109(6):403-7.
https://www.ncbi.nlm.nih.gov/pubmed/23176877

26: Outcomes associated with timing of maintenance treatment for COPD exacerbation. Am J Manag Care. 2012 Sep 1;18(9):e338-45.
https://www.ncbi.nlm.nih.gov/pubmed/23009332

Conference Abstracts and Posters

1. The Cost-Effectiveness of Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Major Surgery in Egypt. Value in Health 2012 (22), S895

2. Profiling Clinical Characteristics and Treatment Patterns among Non-Valvular Atrial Fibrillation Patients: A Real-World Analysis in Dubai, United Arab Emirates. Open Medicine Journal 2019, 6 (1)

3. Budget Impact Analysis of Golimumab in Adult Rheumatoid Arthritis Patients in Kingdom of Saudi Arabia. Value in Health 2019 (22), S47

4. Robotic sacrocolpopexy for pelvic organ prolapse: Nationwide costs, utilization and outcomes ninety days following surgery. Clin Obstet Gynecol 2019 (5), 1-8

5. Treatment Patterns among Newly Diagnosed Diabetes Patients in Dubai. Value in Health 2017, 20 (9), A485

6. Antibiotic Prescribing Pattern in Acute Upper Respiratory Tract infections in Dubai. Value in Health 2017, 20 (9), A794

7. Current practice patterns for management of vulvodynia in the United States. Archives of gynecology and obstetrics 295 (3), 669-674

8. Mesh complications and failure rates after transvaginal mesh repair compared with abdominal or laparoscopic sacrocolpopexy and to native tissue repair in treating apical prolapse. International urogynecology journal 28 (2), 215-222

9. Topical Testosterone Gel Use is Associated with Reduced Risk of CVD Events in Younger Men with CVD Risk Factors and No Increased Risk in Men Aged 65+. Circulation 2016, 133

10. Gender and Bmi-Specific Anticholinergic Persistence and Adherence in Patients with Overactive Bladder. Neurourology and Urodynamics 2016 (35), S58-S58

11. Essure sterilization compared with Mirena IUD among commercially insured population in the United States over a decade. Contraception 2015, 92 (4), 395

12. SNM Efficacy By Diagnostic Category and by Age in a National Database in US. Neurourology and Urodynamics 2015, 34, S376-S376

13. Health Resource Utilization and Costs during First 90 Days following Robotic Assisted Hysterectomy. Journal of Minimally Invasive Gynecology 2015, 22 (3), S11

14. Readmissions and Health Resource Utilization Subsequent to Robotic Sacrocolpopexy. Neurourology and Urodynamics 2015, 34, S86-S87

15. The Disease Burden of Influenza in Germany. Value in Health 2013, 16 (7), A365

16. First-line use of calcipotriene/betamethasone dipropionate combination products for the treatment of plaque psoriasis is associated with lower health care utilization and cost. Value in Health 2013, 16 (3), A117

17. Publication Trends of Budget Impact Analyses Over the Past Six Years. Value in Health 2009, 12 (3), A94

18. An Investigation of Evidence-Based Use of Atypical Antipsychotics in Arkansas Medicaid Pediatric, Value in Health 2008, 11 (3), A130-A131

19. The Impact of a Calcium Channel Blocker Preferred Drug List On Medicaid Prescription Expenditures and Utilization, Value in Health 2007, 10 (3), A3

20. The Trends in Prescribing of Herbal Medicines in Ambulatory Settings in the United States 1993-2004, Value in Health 2007, 10 (3), A25-A26

21. An Investigation of Evidence-based Versus Non Evidence-based Off-label Use of Atypical Antipsychotics in Arkansas Medicaid Pediatric Population, University of Arkansas for Medical Sciences, 2007

22. Comparison of Major Bleeding and Stroke-related Hospital Readmissions among Hospitalized Nonvalvular Atrial Fibrillation Patients Treated With Warfarin And Apixaban in the US. Journal of the American College of Cardiology, Volume 73, Issue 9 Supplement 1, March 2019

23. Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants among Frail Non-valvular Atrial Fibrillation Patients. Journal of the American College of Cardiology, Volume 73, Issue 9 Supplement 1, March 2019

24. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared To Warfarin among Frail Non-valvular Atrial Fibrillation Patients. Journal of the American College of Cardiology, Volume 73, Issue 9 Supplement 1, March 2019

25. Effectiveness and Safety of Apixaban, Dabigatran and Rivaroxaban versus Warfarin in Obese Patients With Nonvalvular Atrial Fibrillation: Aristophanes Subgroup Analysis. Journal of the American College of Cardiology, Volume 73, Issue 9 Supplement 1, March 2019

26. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Obese Non-valvular Atrial Fibrillation Patients: A Pooled Claims Database Analysis. Journal of the American College of Cardiology, Volume 73, Issue 9 Supplement 1, March 2019

27. Comparison of Drug Switching and Discontinuation Rates in Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants in the US. Circulation, Volume 138, Issue Suppl_1

28. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients With Non-Valvular Atrial Fibrillation and Diabetes. Circulation, Volume 138, Issue Suppl_1

29. Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Warfarin Among Patients With Non-Valvular Atrial Fibrillation and Diabetes: ARISTOPHANES Diabetes Subgroup Analysis. Circulation, Volume 138, Issue Suppl_1

30. Non-Vitamin K Antagonist Oral Anticoagulants Associated With Lower Stroke Rates Compared to Warfarin Among Very Elderly Patients With Non-Valvular Atrial Fibrillation: An ARISTOPHANES Subgroup Analysis. Circulation, Volume 138, Issue Suppl_1

31. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Among Very Elderly Patients With Non-Valvular Atrial Fibrillation: An Observational Study. Circulation, Volume 138, Issue Suppl_1

32. Effectiveness, safety, and composite clinical outcomes between apixaban and other oral anticoagulants for non-valvular atrial fibrillation patients in the US Medicare population. European Heart Journal, Volume 39, Issue suppl_1, 1 August 2018, ehy563.P4792

33. Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population. European Heart Journal, Volume 39, Issue suppl_1, 1 August 2018, ehy563.P3844.

34. Comparison of effectiveness, safety, and healthcare costs of direct oral anticoagulants with warfarin in nonvalvular atrial fibrillation patients with heart failure. European Heart Journal, Volume 39, Issue suppl_1, August 2018, ehy566.P6590

35. Comparison of effectiveness, safety, and healthcare costs in non-valvular atrial fibrillation patients with heart failure prescribed direct oral anticoagulants. European Heart Journal, Volume 39, Issue suppl_1, August 2018, ehy564.P979

36. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients: the ARISTOPHANES study. European Heart Journal, Volume 39, Issue suppl_1, 1 August 2018, ehy565.P2567

37. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non- valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study. European Heart Journal, Volume 39, Issue suppl_1, 1 August 2018, ehy565.P2898

38. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: the ARISTOPHANES study. European Heart Journal, Volume 39, Issue suppl_1, 1 August 2018, ehy565.P2568.

39. Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study. European Heart Journal, Volume 39, Issue suppl_1, 1 August 2018, ehy565.P2903.

40. Patients with Nonvalvular Atrial Fibrillation Who Continue Apixaban Treatment Have Lower Healthcare Costs Compared with Patients Who Switch to Another Oral Anticoagulant. J Manag Care Spec Pharm, 2018 Oct;24(10-a Suppl):S63.

41. Healthcare Costs of Direct Oral Anticoagulants Versus Warfarin Among Medicare Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm, 2018 Oct;24(10-a Suppl):S64

42. Nonvalvular Atrial Fibrillation Elderly Patients with Apixaban Treatment Incurred Lower All-Cause, Stroke, and Major Bleeding-Related Costs Versus Dabigatran, Rivaroxaban, and Warfarin. J Manag Care Spec Pharm, 2018 Oct;24(10-a Suppl):S64

43. Examining the Real-World Management of Non-Valvular Atrial Fibrillation Based on Clinical Guidelines. J Manag Care Spec Pharm, 2019 Mar;25(3-a Suppl):S69

44. Treatment Interruption Patterns Among Adalimumab Users in a Commercially Insured Managed Care Population in the US. (Abstract Accepted. Poster to be Presented at the Academy of Managed Care Pharmacy Meeting 2017)

45. Initial Diagnosis and Treatment Patterns by Healthcare Setting among Chronic Obstructive Pulmonary Disease (COPD) patients in the United States. J Manag Care Spec Pharm. 2016 Apr;22(4a): S90

46. Association between COPD Severity and Work Productivity, Quality of Life and Healthcare Resource Use. Am J Respir Crit Care Med 191;2015:A4447

47. Association between Comorbidities and Hospitalizations among Patients with Chronic Obstructive Pulmonary Disease (COPD). J Manag Care Spec Pharm. 2015 Apr;21(4a): S55

48. Association between Non-Adherence to Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications and Medications for other Chronic Conditions. J Manag Care Spec Pharm. 2015 Apr;21(4a): S54

49. Factors Associated with Non-Treatment of COPD: A Cross-Sectional Analysis of the National Health and Wellness Survey Data.

50. Identification of Undiagnosed COPD Patients in a Claims Database Using a Predictive Model. J Manag Care Spec Pharm. 2015 Apr;20(4a): S36

51. COPD-related Exacerbation Frequency and Association with Healthcare Resource Utilization and Costs: A Retrospective Cohort Study using an Administrative Claims Database. J Manag Care Spec Pharm. 2015 Apr;20(4a): S35

52. Factors Associated With Chronic Obstructive Pulmonary Disease-Related Inpatient Readmissions. Value in Health. 2014; 17(3): A147

53. Assessment Of Spirometry Testing And Inpatient Readmission In Patients With Chronic Obstructive Pulmonary Disease. Value in Health. 2014; 17(3): A152

54. Demographic characteristics of asthma subjects that step-down from fluticasone propionate-salmeterol combination therapy. Value in Health. 2014; 16(3): A240–A241

55. Avoidance of futile treatment and adverse events by using angiogenesis-specific imaging for early detection of disease progression in patients with first-line metastatic renal cell carcinoma. Presented at the ASCO’s Quality Care Symposium, November 30 – December 1, 2012 in San Diego, CA

56. Economic evaluation of reduced futile 1st line therapy in metastatic renal cell carcinoma patients using early angiogenesis-specific imaging. Value in Health. 2014; 15(7): A353

57. Economic And Clinical Burden Of Chronic Obstructive Pulmonary Disease (COPD) In The Medicaid Population. Presented at the American Thoracic Society 2012 International Conference, May 8-12, 2012, San Francisco, California.

58. Fluticasone propionate/Salmeterol is Associated with a Higher Likelihood of Achieving an Optimal Controller-to-Total Asthma Medication Ratio Compared to Inhaled Corticosteroid Alone. J Allergy Clin Immunol 129; 2012 (2): AB42

59. Impact of early versus delayed maintenance treatment following discharge from a COPD-related hospitalization/ED visit on exacerbations and costs in a managed care population. Am J Respir Crit Care Med 183; 2011:A1474

60. Impact of initiating fluticasone propionate-salmeterol combination 250/50mcg (FSC) following a hospitalization or emergency department visit related to Chronic Obstructive Pulmonary Disease (COPD). Am J Respir Crit Care Med 183;2011:A1482

61. The incremental impact of increasing the controller-to-total asthma medication ratio on risk of future asthma-related events in Medicaid pediatric patients with asthma. Am J Respir Crit Care Med 183;2011:A1284

62. Assessment of albuterol use and risk of asthma-related events in Medicaid. Am J Respir Crit Care Med 183;2011:A1285

63. Assessment of Metabolic Monitoring of Patients Prescribed Second Generation Antipsychotics (SGAs) using Electronic Medical Record (EMR) Data. Value in Health 2010; 13(3): A99